Ovid Therapeutics has hit the bottom of the range in its IPO, resulting in it grossing $75 million.

Newly born European biotech Vivet Therapeutics has started life with €37.5 million ($41 million) and an executive team made up of Novartis, Sanofi and Gensight…

While you’re searching for, statistically speaking, cat videos, Alphabet’s venture arm GV is searching for life sciences companies that are working on new ways…

Boehringer Ingelheim has joined with Kurma Partners and Idinvest to lead a €20 million Series A in checkpoint inhibitor startup ImCheck Therapeutics.

Robert Plenge is to take the plunge and leave his role at Merck as VP and head of translational medicine to take up a new position at Celgene to run its…

Infectious disease specialist Arsanis has raised a solid chunk of cash as it picks up the Gates Foundation and Alphabet's GV as backers.

Sienna Biopharmaceuticals has raised $40 million to advance its pipeline of clinical-phase aesthetic and dermatology assets.

Argenx has filed to raise up to $75 million in a Nasdaq IPO to take lead candidate ARGX-113 to the cusp of a pivotal trial.

A new survey of U.S. scientists, FDA researchers and biomedical clinicians has found that most are concerned over FDA Commissioner nominee Scott Gottlieb’s…

Venture Capital